WO2011147926A3 - Magnetically responsive membrane structures - Google Patents

Magnetically responsive membrane structures Download PDF

Info

Publication number
WO2011147926A3
WO2011147926A3 PCT/EP2011/058654 EP2011058654W WO2011147926A3 WO 2011147926 A3 WO2011147926 A3 WO 2011147926A3 EP 2011058654 W EP2011058654 W EP 2011058654W WO 2011147926 A3 WO2011147926 A3 WO 2011147926A3
Authority
WO
WIPO (PCT)
Prior art keywords
magnetically responsive
vesicular
attachment
membrane structures
compositions
Prior art date
Application number
PCT/EP2011/058654
Other languages
French (fr)
Other versions
WO2011147926A2 (en
Inventor
Erik Reimhult
Esther Amstad
Marcus Textor
Original Assignee
Erik Reimhult
Esther Amstad
Marcus Textor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erik Reimhult, Esther Amstad, Marcus Textor filed Critical Erik Reimhult
Priority to EP11723036.7A priority Critical patent/EP2575896A2/en
Publication of WO2011147926A2 publication Critical patent/WO2011147926A2/en
Publication of WO2011147926A3 publication Critical patent/WO2011147926A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • A61K49/1812Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1839Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention is directed towards magnetically responsive vesicular compositions comprising (a) a vesicular structure having a membrane enclosing a cavity and (b) at least one stabilized magnetic nanoparticle embedded in said membrane, and in particular towards lipid and/or polymeric vesicular compositions comprising stabilized superparamagnetic iron oxide nanoparticles. The vesicular compositions may further be functionalized with reactive groups for attachment of active agents or tethers for attachment to surfaces. Methods of preparation and their use in (targeted) delivery of an active agent, as a nanoreactor, for imaging purposes and combinations thereof are also disclosed.
PCT/EP2011/058654 2010-05-26 2011-05-26 Magnetically responsive membrane structures WO2011147926A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11723036.7A EP2575896A2 (en) 2010-05-26 2011-05-26 Magnetically responsive membrane structures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10163865 2010-05-26
EP10163865.8 2010-05-26

Publications (2)

Publication Number Publication Date
WO2011147926A2 WO2011147926A2 (en) 2011-12-01
WO2011147926A3 true WO2011147926A3 (en) 2012-05-31

Family

ID=44626661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/058654 WO2011147926A2 (en) 2010-05-26 2011-05-26 Magnetically responsive membrane structures

Country Status (2)

Country Link
EP (1) EP2575896A2 (en)
WO (1) WO2011147926A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2666456A1 (en) 2012-05-21 2013-11-27 Natura Bisse International, S.A. Cometic compositions comprising magnetosomes and uses thereof
PT3092012T (en) * 2014-01-07 2019-09-18 Colorobbia Italiana Spa Magnetic nanoparticles functionalized with cathecol, production and use thereof
EP3139964B1 (en) * 2014-05-06 2019-04-24 Memorial Sloan Kettering Cancer Center Magnetoenzymatic carrier system for imaging and targeted delivery and release of active agents
EP3162361A1 (en) 2015-11-02 2017-05-03 Universität für Bodenkultur Wien Improved magnetically reactive vesicular bodies
FR3045408B1 (en) * 2015-12-18 2021-01-08 Centre Nat Rech Scient ASSEMBLIES OF HYDROPHOBIC NANOPARTICLES IN AQUEOUS MEDIUM
WO2017197310A1 (en) * 2016-05-13 2017-11-16 University Of Maryland Synthesis and functionalization of highly monodispersed iron and iron core/iron oxide shell magnetic particles with broadly tunable diameter
CN110947363A (en) * 2019-12-04 2020-04-03 四川农业大学 Magnetic-drive light carbon sponge for oil-water separation and preparation method thereof
AU2021342431A1 (en) * 2020-09-16 2023-07-13 Imagion Biosystems, Inc. Methods and apparatuses for the synthesis of drug-loaded magnetic micelle aggregates
CN115121007A (en) * 2021-03-24 2022-09-30 南开大学 Dynamic intelligent membrane based on pH-magnetism dual response and used for efficiently and accurately separating complex oil-water system

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011023A1 (en) * 1994-10-10 1996-04-18 Nycomed Salutar Inc. Liposomal agents
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6251365B1 (en) * 1997-03-07 2001-06-26 Max-Delbruck-Centrum Fur Molekulare Medizin And Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Specific magnetosome, method for the production and use thereof
WO2007021236A1 (en) * 2005-08-19 2007-02-22 Genovis Ab A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle
US20070154397A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Thermosensitive nanostructure for hyperthermia treatment
US20090004258A1 (en) * 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
WO2009042895A2 (en) * 2007-09-26 2009-04-02 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response
US20110059020A1 (en) * 2009-09-08 2011-03-10 Fujifilm Corporation Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same
WO2011061259A1 (en) * 2009-11-18 2011-05-26 Nanobacterie Treatment of cancer or tumor induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field
WO2011128896A1 (en) * 2010-04-12 2011-10-20 Ramot At Tel-Aviv University Ltd. Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
WO2012030134A2 (en) * 2010-08-30 2012-03-08 Hanwha Chemical Corporation Iron oxide nanocapsules, method of manufacturing the same, and mri contrast agent using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3619746A1 (en) 1986-06-12 1987-12-17 Basf Ag SUPER PARAMAGNETIC SOLID PARTICLES
US5729511A (en) 1991-02-15 1998-03-17 Discovision Associates Optical disc system having servo motor and servo error detection assembly operated relative to monitored quad sum signal
IT1254135B (en) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti ACIL CARNITINE ESTERS WITH LONG CHAIN ALIPHATIC ALCOHOLS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, WITH ANTIBACTERIAL ACTIVITY.

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
WO1996011023A1 (en) * 1994-10-10 1996-04-18 Nycomed Salutar Inc. Liposomal agents
US6251365B1 (en) * 1997-03-07 2001-06-26 Max-Delbruck-Centrum Fur Molekulare Medizin And Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Specific magnetosome, method for the production and use thereof
WO2007021236A1 (en) * 2005-08-19 2007-02-22 Genovis Ab A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle
US20070154397A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Thermosensitive nanostructure for hyperthermia treatment
US20090004258A1 (en) * 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
WO2009042895A2 (en) * 2007-09-26 2009-04-02 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response
US20110059020A1 (en) * 2009-09-08 2011-03-10 Fujifilm Corporation Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same
WO2011061259A1 (en) * 2009-11-18 2011-05-26 Nanobacterie Treatment of cancer or tumor induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field
WO2011128896A1 (en) * 2010-04-12 2011-10-20 Ramot At Tel-Aviv University Ltd. Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
WO2012030134A2 (en) * 2010-08-30 2012-03-08 Hanwha Chemical Corporation Iron oxide nanocapsules, method of manufacturing the same, and mri contrast agent using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ESTHER AMSTAD ET AL: "Triggered Release from Liposomes through Magnetic Actuation of Iron Oxide Nanoparticle Containing Membranes", NANO LETTERS, vol. 11, no. 4, 13 April 2011 (2011-04-13), pages 1664 - 1670, XP055023851, ISSN: 1530-6984, DOI: 10.1021/nl2001499 *
ESTHER AMSTAD ET AL: "Ultrastable Iron Oxide Nanoparticle Colloidal Suspensions Using Dispersants with Catechol-Derived Anchor Groups", NANO LETTERS, vol. 9, no. 12, 9 December 2009 (2009-12-09), pages 4042 - 4048, XP055023825, ISSN: 1530-6984, DOI: 10.1021/nl902212q *

Also Published As

Publication number Publication date
EP2575896A2 (en) 2013-04-10
WO2011147926A2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
WO2011147926A3 (en) Magnetically responsive membrane structures
WO2011017690A3 (en) Intracellular delivery of contrast agents with functionalized nanoparticles
NZ622843A (en) Improved lipid formulation
WO2011119995A3 (en) Formulations and methods of use
WO2006108405A3 (en) Nanoparticle/active ingredient conjugate
BRPI1014854A2 (en) "polymer-agent conjugates, particles, compositions, and related methods of use"
IL221886A (en) Composition comprising nanoparticles comprising a taxane and an albumin, combinations of the composition with other agents and uses thereof
TR201906255T4 (en) Stable formulations for lyophilizing therapeutic particles.
EP2285350A4 (en) Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
WO2010091183A3 (en) Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
EP2348834A4 (en) Methods to produce polymer nanoparticles and formulations of active ingredients
EP2673006A4 (en) Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
WO2011017456A3 (en) Localized delivery of nanoparticles for therapeutic and diagnostic applications
WO2010076237A3 (en) Nanoparticle contrast agents for diagnostic imaging
WO2010059253A3 (en) Methods and compositions for localized agent delivery
EP2600903A4 (en) Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and mri t1 contrast agents using the same
WO2009016433A3 (en) Oncolytic rhabdovirus
WO2011150212A3 (en) Magnetic nanoparticles
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2007141050A3 (en) Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications
WO2011081430A3 (en) Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
WO2011070440A3 (en) Oncolytic rhabdovirus
WO2010129819A3 (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
EP2432460A4 (en) Water dispersible glyceryl monooleate magnetic nanoparticle formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11723036

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011723036

Country of ref document: EP